Altamira Therapeutics Ltd.
CYTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | – | $0 | $0 | $0 |
| % Growth | – | -100% | 378.4% | – |
| Cost of Goods Sold | – | $0 | $0 | $0 |
| Gross Profit | – | $0 | -$0 | -$0 |
| % Margin | – | – | -372.4% | -3,407.3% |
| R&D Expenses | – | $0 | $0 | $0 |
| G&A Expenses | – | $0 | $0 | $0 |
| SG&A Expenses | – | $0 | $0 | $0 |
| Sales & Mktg Exp. | – | $0 | $0 | $0 |
| Other Operating Expenses | – | $0 | $0 | $0 |
| Operating Expenses | – | $0 | $0 | $0 |
| Operating Income | – | -$0 | -$0 | -$0 |
| % Margin | – | – | -5,894.3% | -8,361.4% |
| Other Income/Exp. Net | – | -$0 | -$0 | -$0 |
| Pre-Tax Income | – | -$0 | -$0 | -$0 |
| Tax Expense | – | $0 | -$0 | -$0 |
| Net Income | – | -$0 | -$0 | -$0 |
| % Margin | – | – | -8,680.2% | -26,703.1% |
| EPS | – | -14.81 | -582.58 | -515.11 |
| % Growth | – | 97.5% | -13.1% | – |
| EPS Diluted | – | -14.8 | -582.58 | -515.11 |
| Weighted Avg Shares Out | – | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | – | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | – | $0 | $0 | $0 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | – | $0 | $0 | $0 |
| EBITDA | – | -$0 | -$0 | -$0 |
| % Margin | – | – | -5,770.6% | -10,512.8% |